Date: 2015-08-19
Type of information: Company acquisition
Acquired company: Kapa Biosystems (USA - MA)
Acquiring company: Roche (Switzerland)
Amount: undisclosed
Terms: * On August 19, 2015, Roche announced that it has signed a definitive agreement to acquire Kapa Biosystems, a privately-held company headquartered in Wilmington, Massachusetts, US. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications. “This acquisition builds on Roche’s commitment to develop a differentiated NGS portfolio that will provide our customers with a complete genetic testing solution,” said Roland Diggelmann, COO Roche Diagnostics Division. The transaction is subject to customary closing conditions. Financial terms of the transaction are not disclosed.
Details: Kapa Biosystems, co-founded by Trey Foskett, Paul McEwan, Ron McEwan and Chris McGuinness in 2006, has pioneered the use of directed evolution to develop a suite of high-performance reagents for a range of life science applications. The company is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications. Kapa’s proprietary protein engineering technology is highly customizable and allows for the generation and screening of large numbers of enzyme variants. Tailored enzymes with improved performance for specific applications can be rapidly selected, expediting product development timelines. Kapa`s impressive portfolio of NGS reagents includes enzymes such as novel DNA polymerases, with the potential to improve the performance of the entire sequencing workflow.
Related: Technology - Services
